Stockpolly
Search
ORKA · NASDAQ · Biotechnology

Oruka Therapeutics (ORKA)

Develops extended-half-life antibodies for psoriasis, hidradenitis suppurativa and related inflammatory diseases.

$91.70
Pre-market−0.02 (−0.02%)
At close$91.72(−0.42%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
222212938252834343650
Research & development000192632202429282943
222346545777
Selling & marketing000000000000
General & administrative002346545000
Other expenses00100—000000
Operating income−2−2−2−21−29−38−25−28−34−34−36−50
110−115444559
Interest income110015444559
Interest expense000010000000
Other non-operating income−1−101−1−1−4−4−4−5−50
Income before tax−1−1−2−22−29−33−21−25−30−30−32−41
Net income from continuing operations−1−1−2−22−29−33−21−25−30−30−32−41
Net income−1−1−2−22−29−33−21−25−30−30−32−41
EPS, basic−$1.19−$0.90−$0.24−$1.30−$1.91−$1.54−$0.50−$0.58−$0.69−$0.54−$0.58−$0.66
EPS, diluted−$1.19−$0.90−$0.24−$1.30−$1.91−$1.54−$0.50−$0.58−$0.69−$0.54−$0.58−$0.66
Weighted average shares, basic141415151517424244545563
Weighted average shares, diluted141415151517424244545563
EBITDA−1−1−2−22−28−37−21−25−30−30−32−50
Depreciation & amortization000000000000
EBIT−1−1−2−22−28−37−21−25−30−30−32−50